GlassScriptPhysician profile
Petra Lynch
NPI 1184896755
$3,451.23
in general payments reported to CMS, 2019-2025
25 companies · $745 in 2025
The $745 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $601 · 2021: $794 · 2022: $607 · 2023: $16.11 · 2024: $17.67 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $384.23 | 2019-2021 | |
| Amgen INC. | $362.89 | 2019-2022 | |
| Novo Nordisk INC | $335.89 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $264.72 | 2019-2023 | |
| Scpharmaceuticals INC. | $263.11 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.54 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $211.97 | 2020-2021 | |
| Pfizer INC. | $179.76 | 2019-2021 | |
| Abbott Laboratories | $163.64 | 2025 | Mitraclip |
| Abiomed | $127.17 | 2025 | |
| Janssen Pharmaceuticals, INC | $115.71 | 2019-2022 | |
| Chiesi USA, INC. | $112.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.38 | 2019-2022 | |
| Lilly USA, LLC | $94.82 | 2025 | Zepbound |
| Medtronic, INC. | $89.84 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $72.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $68.75 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.09 | 2019-2021 | |
| Medtronic Vascular, INC. | $51.06 | 2019 | |
| Lantheus Medical Imaging, INC. | $46.71 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.92 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $23.59 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $20.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2022 | |
| Philips North America LLC | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petra Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.